TIL and Anti-PD1 in Metastatic Melanoma

NCT03638375 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Toxicity, Drug
Adverse Drug Event
Effects of Immunotherapy

Interventions

DRUG: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha

Sponsor

Leiden University

Collaborators

[object Object]